<DOC>
	<DOC>NCT02789176</DOC>
	<brief_summary>The purpose of this study is to examine whether the duration of treatment with phenobarbital has an impact on neurodevelopmental and epilepsy outcomes, as well as parent and family well-being, after neonatal seizures.</brief_summary>
	<brief_title>Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study</brief_title>
	<detailed_description>The Nature of the comparison analysis for parent and family well-being is yet to be determined with our Parent Partner Advisory Board.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Neonates &lt;44 weeks corrected age at seizure onset Seizures due to acute brain injury Parent(s) who are English or Spanish literate (with assistance of interpreter) Neonates at risk for adverse outcome independent of seizures and underlying brain injury Neonates with mild, temporary causes for seizures Newborns with neonatalonset epilepsy syndromes Neonates who do not survive the initial hospital admission Neonates will not be excluded based on race, ethnicity, gender or gestational age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phenobarbital</keyword>
	<keyword>EEG</keyword>
	<keyword>family impact</keyword>
	<keyword>neurodevelopment</keyword>
</DOC>